Clinical trials: Type 1 Diabetes
Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease.
- Conditions
- Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
- Trial name
- NCT01030861
- Testing
- Teplizumab
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 76 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HTLV-I Infection, T Cell Leukemia
Anti-Tac for Treatment of Leukemia
The purpose of the study was to determine: (1) the toxicity and maximum tolerated dose (MTD) of humanized anti-Tac (daclizumab), (Zenapax(Registered Trademark)) in patients with adult T-cell leukemia/lymphoma (ATL); (2) to define…
- Trial name
- NCT00001941
- Testing
- daclizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Diabetes Mellitus Type 1
The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas
This study will compare two different models of a wearable bionic pancreas device (the iPhone-based bionic pancreas vs. the iLet bionic pancreas) in adult participant with type 1 diabetes.
- Trial name
- NCT02701257
- Testing
- iPhone bionic pancreas, iLet bionic pancreas, Xeris Xerisol glucagon
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Type 2 Diabetes, Men
PowerUp for Health: A Diabetes Prevention Program for Men
The purpose of this two-year proposal is to: 1. develop and 2. complete a pilot test of an adaptation of the evidence-based National Diabetes Prevention Program (NDPP) tailored to engage men with prediabetes in disadvantaged…
- Trial name
- NCT02555631
- Testing
- lifestyle
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Type 1 Diabetes
Closed-loop Glucose Control for Automated Management of Type 1 Diabetes
We hypothesize that our integrated closed-loop glucose-control system can provide effective, tight, and safe blood glucose (BG) control in type 1 diabetes, thereby establishing the feasibility of closed-loop BG control.
- Trial name
- NCT00811317
- Testing
- Closed-loop
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Boston University Charles River Campus
Diabetes Mellitus, Type 1
A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus
Two forms of insulin lispro (LY900014 and Humalog®) and two forms of insulin aspart (NovoRapid® and Fiasp®) will be given to trial participants with diabetes mellitus type 1 by injection under the skin.
- Trial name
- NCT03449433
- Testing
- LY900014, Insulin Lispro, Insulin Aspart
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Hypoglycemia Unawareness
Assessment of the Impact of Real-Time Continuous Glucose Monitoring on People Presenting With Severe Hypoglycaemia
This study aims to assess the impact of real-time continuous glucose monitoring on the frequency, duration, awareness and severity of hypoglycaemia in people with type 1 diabetes and a recent history of severe hypoglycaemia…
- Conditions
- Diabetes Mellitus, Type 1, Hypoglycemia Unawareness, Hypoglycemia
- Trial name
- AIR-CGM (NCT03748433)
- Testing
- Dexcom G6 CGM, Tandem t:slim X2 Insulin Pump
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- Imperial College London
Type 1 Diabetes Mellitus
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)
- Trial name
- NCT01498185
- Testing
- Dapagliflozin
- Where
- 12 sites in United States
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)
This clinical trial will explore the safety and effect of autologous ex vivo expanded polyclonal regulatory T-cells on beta cell function in patients, aged 8 to 17, with recent onset T1DM.
- Trial name
- NCT02691247
- Testing
- CLBS03 Low Dose, CLBS03 High Dose
- Where
- 15 sites in United States
- Volunteers
- 113 people
- Sponsor
- Lisata Therapeutics, Inc.
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT04436822
- Testing
- Continuous Glucose Monitoring
- Where
- 18 sites in United States, China
- Volunteers
- 317 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Type 1
CGM Precision and Glycaemic Variability
Use of devices for continuous monitoring of the blood sugar is valuable for people with diabetes to understand their disease and to help prevent low blood sugar.
- Trial name
- NCT03842683
- Testing
- CGM
- Volunteers
- 472 people
- Sponsor
- Peter Vestergaard
Type 1 Diabetes Mellitus
Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation
The purposes of this study are: 1. To reverse hyperglycemia and insulin dependency in patients with type 1 diabetes mellitus through islet transplantation utilizing steroid free, calcineurin-inhibitor free immunosuppression. 2.
- Trial name
- NCT00315627
- Testing
- Islet transplantation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Rodolfo Alejandro
Type 1 Diabetes
In Clinic Evaluation of the PLGM Feature
This study is a multi-center, single arm and in-clinic study to evaluate the safety of the PLGM System and its algorithm with the Enlite 3 Sensor.
- Trial name
- PLGM (NCT02130284)
- Testing
- Predictive Low Glucose Management Feature in Insulin pump
- Where
- 8 sites in United States
- Volunteers
- 80 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes, Hypoglycemia
Islet Allotransplantation With Steroid Free Immunosuppression
The restoration of endogenous insulin secretion carries significant hopes for shifting the paradigm of life long exogenous insulin therapy in selected groups of patients with type 1 diabetes(T1D).
- Conditions
- Type 1 Diabetes, Hypoglycemia, Metabolic Diseases
- Trial name
- NCT00446264
- Testing
- islet transplantation, daclizumab - sirolimus - tacrolimus
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Lille
Type 1 Diabetes Mellitus, Hypoglycemia
Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes
The primary objective of this protocol is to test the safety and efficacy of a treatment regimen consisting of maintenance therapy with efalizumab and sirolimus for 1 year followed by withdrawal of efalizumab and maintenance…
- Trial name
- RAPTIVA (NCT00672204)
- Testing
- Allogeneic islets of Langerhans transplant, Raptiva, Sirolimus
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Minnesota
Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1
Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) results from the autoimmune destruction of insulin-producing ß cells. Although exogenous insulin is widely available, it is not possible for affected individuals to consistently achieve euglycemia…
- Conditions
- Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1, Type 1 Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus 1
- Trial name
- NCT01781975
- Testing
- Imatinib Mesylate
- Where
- 9 sites in United States, Australia
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Metastatic Pancreatic Adenocarcinoma
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
This study will enroll patients who have metastatic pancreatic cancer with stable disease on FOLFIRINOX chemotherapy. The main purpose of this study is to compare survival between patients that receive ipilimumab and a pancreatic…
- Trial name
- NCT01896869
- Testing
- Ipilimumab, Vaccine, FOLFIRINOX
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Type 1 Diabetes Mellitus
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
Subjects will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 94-day (13-week) hybrid closed-loop phase conducted in an outpatient setting…
- Trial name
- NCT04476472
- Testing
- Omnipod Horizon™ Automated Glucose Control System
- Where
- 10 sites in United States
- Volunteers
- 80 people
- Sponsor
- Insulet Corporation
Diabetes Mellitus, Type 1
ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)
This post-market, interventional, prospective, single arm, the United States (US) based multi-center study will assess the change in treatment satisfaction of participants who utilize the ACCU-CHEK Connect Diabetes Management…
- Trial name
- NCT02600845
- Testing
- ACCU-CHEK
- Where
- 11 sites in United States
- Volunteers
- 122 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes Mellitus
Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker
The purpose of this study is to see if the Artificial Pancreas Platform (AP Platform = Cell Phone + Closed Loop Control) can successfully control blood sugar in people with type 1 diabetes mellitus on insulin pump therapy in a…
- Trial name
- NCT01582139
- Testing
- Heart rate informed SSM+HMM
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Virginia